Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
Key Highlights
- ➤Invivyd (IVVD) presented preclinical data for measles monoclonal antibody candidate VMS063
- ➤VMS063 showed potent in vitro neutralization against contemporary variants including B3 and D8
- ➤Invivyd initiated manufacturing scale-up targeting clinical development of VMS063 in 2027
- ➤VMS063 is being developed in intramuscular or subcutaneous forms for prevention and treatment
Expert Statements
Michael Mina, M.D., Ph.D., Chief Medical Officer and Chief Epidemiologist of Invivyd
“Despite continued transmission of measles globally, and a reemergence in the United States, physicians who see measles patients have long lamented that there are no targeted approved treatments for measles. More generally, there has been little, if any, innovation in how we prevent and treat measles since 1963. As we see more and more cases, it’s clear that Americans, as well as the international community, need additional prevention options for measles as well as a specific treatment. A molecule like VMS063 has the potential to transform the measles landscape by leveraging the extraordinary potential of monoclonal antibodies that can, with one molecule, provide both prevention and treatment to fill these gaps. We are excited to interact with the scientific and public health community at IDWeek 2026™, as well as leaders across public health more generally, and we are rapidly advancing this program toward clinical development.”
* VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd * VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants, and attractive biophysical properties supporting its potential utility for both treatment and prevention of measles * Invivyd is scaling up production toward clinical development in 2027 * There are currently no FDA approved treatments for measles, leaving a major gap in the public health and medical management of measles * The U.S. is experiencing a record-breaking number of measles cases in 2026, and a significant immunity gap has emerged, leaving millions of Americans vulnerable to measles infection and associated complications NEW HAVEN, Conn., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the presentation of preclinical data describing its novel, potential first- and best-in-class investigational monoclonal antibody candidate VMS063 at IDWeek 2026™ in Washington, D.C. Data demonstrated highly potent in vitro antiviral activity against contemporary measles fusion protein (MeV-F) variants, supporting its potential utility for both treatment and prevention (pre/post-exposure prophylaxis) of measles.
Get started
Create a free account to read the full story.